Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

2,589 questions in 168 reviews · Schizophrenia

current versions

No studies 601 · 23.2%Ungraded 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
BIFEPRUNOX vs PLACEBO Mental state: 1. Mean change PANSS positive subscale (lower value = good) · People with schizophrenia Bifeprunox versus placebo for schizophrenia (2016) · Cochrane	no estimate extracted	2 studies · 549 participants	Low
BIFEPRUNOX vs PLACEBO Mental state: 2. Mean change PANSS negative subscale (lower value = good) · People with schizophrenia Bifeprunox versus placebo for schizophrenia (2016) · Cochrane	no estimate extracted	2 studies · 549 participants	Low
BIFEPRUNOX vs PLACEBO Service use: Re‐admission · People with schizophrenia Bifeprunox versus placebo for schizophrenia (2016) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
BIFEPRUNOX vs PLACEBO Global state: Deteriorated CGI · People with schizophrenia Bifeprunox versus placebo for schizophrenia (2016) · Cochrane	RR 0.71 [0.54, 0.93]	1 study · 231 participants	Very low
BIFEPRUNOX vs PLACEBO Quality of life: Important change · People with schizophrenia Bifeprunox versus placebo for schizophrenia (2016) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
BIFEPRUNOX vs PLACEBO Adverse effects: Weight ‐ Total number of participants with ≥ 7% weight increase · People with schizophrenia Bifeprunox versus placebo for schizophrenia (2016) · Cochrane	RR 1.02 [0.31, 3.33]	1 study · 483 participants	Moderate
BIFEPRUNOX vs PLACEBO Economics: Cost · People with schizophrenia Bifeprunox versus placebo for schizophrenia (2016) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
CHLORPROMAZINE vs RESERPINE Global state: Not improved (short term) · patients with schizophrenia Chlorpromazine versus reserpine for schizophrenia (2016) · Cochrane	RR 0.75 [0.62, 0.92]	6 studies · 781 participants	Low
CHLORPROMAZINE vs RESERPINE Mental state: Not improved (paranoid distortion) Multidimentional Scale for Rating Psychiatric Patients (short term) · patients with schizophrenia Chlorpromazine versus reserpine for schizophrenia (2016) · Cochrane	RR 1.33 [0.62, 2.89]	1 study · 19 participants	Very low
CHLORPROMAZINE vs RESERPINE Functioning: not improved occupational adjustment (short term) · patients with schizophrenia Chlorpromazine versus reserpine for schizophrenia (2016) · Cochrane	RR 0.83 [0.47, 1.47]	1 study · 40 participants	Moderate
CHLORPROMAZINE vs RESERPINE Adverse events ‐ toxic reaction (short term) · patients with schizophrenia Chlorpromazine versus reserpine for schizophrenia (2016) · Cochrane	RR 1.68 [0.43, 6.54]	3 studies · 210 participants	Moderate
CHLORPROMAZINE vs RESERPINE Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia Chlorpromazine versus reserpine for schizophrenia (2016) · Cochrane	RR 1.16 [0.94, 1.42]	4 studies · 229 participants	Moderate
CHLORPROMAZINE vs RESERPINE Behaviour: Not improved ‐ general (medium term) · patients with schizophrenia Chlorpromazine versus reserpine for schizophrenia (2016) · Cochrane	RR 0.79 [0.41, 1.53]	1 study · 98 participants	Moderate
CHLORPROMAZINE vs RESERPINE Quality of life: Not improved to an important extent · patients with schizophrenia Chlorpromazine versus reserpine for schizophrenia (2016) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral health education (advice and training) vs Standard care (oral health advice not specifically emphasised beyond usual care) Quality of life: Chronic pain · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane	No study reported useable data	0 studies	No studies
Motivational interview plus oral health education vs Oral health education Oral health: Not brushing teeth twice a day · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane	No study reported useable data	0 studies	No studies
Motivational interview plus oral health education vs Oral health education Oral health: Not having seen a dentist in the past year · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per… Oral health education (advice and training) for people with serious mental illness (2016) · Cochrane	No study reported useable data	0 studies	No studies
FLUPHENAZINE DECANOATE vs PLACEBO Death · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 5 [0.25, 99.51]	1 study · 54 participants	Very low
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS No clinically important global change · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 0.85 [0.56, 1.27]	1 study · 102 participants	Very low
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Hospital admission ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Leaving the study early · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 0.96 [0.73, 1.25]	10 studies · 937 participants	Low
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Mental state BPRS endpoint score · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	1 study · 120 participants	Very low
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Extrapyramidal adverse effects ‐ general · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 0.47 [0.24, 0.91]	3 studies · 259 participants	Very low
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Death ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Relapse · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 2.43 [0.71, 8.32]	1 study · 49 participants	Very low
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Clinically significant change in global state ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Hospital admission ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Leaving the study early · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 2.43 [0.71, 8.32]	1 study · 49 participants	Very low
FLUPHENAZINE DECANOATE vs PLACEBO Relapse · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 0.62 [0.24, 1.6]	3 studies · 196 participants	Very low
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Mental State BPRS · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	1 study · 39 participants	Very low
FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE Extrapyramidal adverse effects ‐ general · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 1.14 [0.79, 1.64]	2 studies · 49 participants	Very low
FLUPHENAZINE DECANOATE vs PLACEBO Clinically significant change in global state ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANOATE vs PLACEBO Hospital admission ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANOATE vs PLACEBO Leaving the study early · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 1.3 [0.77, 2.19]	4 studies · 216 participants	Very low
FLUPHENAZINE DECANOATE vs PLACEBO Mental state BPRS · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	1 study · 16 participants	Very low
FLUPHENAZINE DECANOATE vs PLACEBO Extrapyramidal adverse effects ‐ tardive dyskinesia · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 0.83 [0.62, 1.11]	1 study · 54 participants	Very low
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Death ‐ not reported · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	no estimate extracted	NR	No studies
FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS Relapse · patients with schizophrenia Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane	RR 1.46 [0.75, 2.83]	6 studies · 419 participants	Very low
CRISIS INTERVENTION vs STANDARD CARE Global state Global Assessment Scale (GAS) · patients with people with severe mental illnesses Crisis intervention for people with severe mental illnesses (2015) · Cochrane	no estimate extracted	1 study · 142 participants	Moderate
CRISIS INTERVENTION vs STANDARD CARE Mental state ‐ general Brief Psychiatric Rating Scale (BPRS) · patients with people with severe mental illnesses Crisis intervention for people with severe mental illnesses (2015) · Cochrane	no estimate extracted	2 studies · 248 participants	Low
CRISIS INTERVENTION vs STANDARD CARE Patient Satisfaction Client Satisfaction Questionnaire (CSQ‐8) · patients with people with severe mental illnesses Crisis intervention for people with severe mental illnesses (2015) · Cochrane	no estimate extracted	1 study · 137 participants	Moderate
CRISIS INTERVENTION vs STANDARD CARE Quality of Life Manchester Short Assessment (MANSA) · patients with people with severe mental illnesses Crisis intervention for people with severe mental illnesses (2015) · Cochrane	no estimate extracted	1 study · 226 participants	Low
CRISIS INTERVENTION vs STANDARD CARE Burden on family Numbers of families stating that overall burden is great · patients with people with severe mental illnesses Crisis intervention for people with severe mental illnesses (2015) · Cochrane	RR 0.34 [0.2, 0.59]	1 study · 120 participants	Low
CRISIS INTERVENTION vs STANDARD CARE Hospital use Repeat admissions excluding index admission · patients with people with severe mental illnesses Crisis intervention for people with severe mental illnesses (2015) · Cochrane	RR 0.75 [0.5, 1.13]	1 study · 369 participants	High
'As required' medication vs regular timed medication Mental state: important change in mental state · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Behaviour: important change in behaviour · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Behaviour: aggression · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Dosage: important difference in dose used · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Adverse events: important adverse events · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies
'As required' medication vs regular timed medication Satisfaction with care: important change in satisfaction with care · seriously mentally ill people in hospital 'As required' medication regimens for seriously mentally ill people in hospital (2015) · Cochrane	no estimate extracted	NR	No studies